

1. Abouassaly *et al.* Epidemiology, etiology, and prevention of prostate cancer. Dalam : Campbell-Walsh Urology Tenth Edition. Philadelphia: Saunders. 2012. Page 2690
2. Bartsch G, Catalona W, Gospodarowicz M. Developments in the treatment of localized prostate cancer. In: McConnell J, Dennis L, Akaza H, Khoury S, Schalken J, editors. Prostate cancer: 6th international consultation on new developments in prostate cancer and prostate diseases. Paris: Health Publication; 2006. p. 277-308.
3. Beckendorf V, Guerif S, Le Prisé E. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. *Int J Radiat Oncol Biol Phys* 2011 Jul;80(4):1056-63.
4. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM. Long-term *survival* after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. *Journal Cancer* 2011;117:2883-91.
5. Brassell SA, Rice KR, Parker PM. Prostate Cancer in Men Aged 70 Years Old or Older, Indolent or Aggressive: Clinicopathological Analysis and Outcomes *J Urol*. 2011;185:132-137
6. Dearnaley DP, Jovic G, Syndikus I. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. *Lancet Oncol* 2014 Apr;15(4):464-73.
7. Epstein JI. An Update of the Gleason Grading system. *J Urol* 2010; 183: 433 – 440
8. James ND, Spears MR, Clarke NW. *Survival* with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). *Eur Urol* 2014 Oct 6. pii: S0302-2838(14)00969-5.



9. Jones CU, Hunt D, McGowan DG. Radiotherapy and short-term androgen deprivation for localized prostate cancer. *N Engl J Med* 2011 Jul;365(2):107-18.
10. Kuban DA, Levy LB, Cheung MR. Long-term failure patterns and *survival* in a randomized dose-escalation trial for prostate cancer. Who dies of disease? *Int J Radiat Oncol Biol Phys* 2011 Apr;79(5):1310-7.
11. Massengill JC, Sun L, Moul JW. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. *J Urol*. 2003;169:1670-1675.
12. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw* 2012;10:1081-7.
13. Mottet N *et al.* Guideline on prostate cancer. *European Urological Association*, 2015.
14. Mottet N, Schalken JA, Heidenreich A, Bastian PJ, Irani J, Salomon L. Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007. *Eur Urol Suppl* 2008;7:460-73.
15. Mottet N, Peneau M, Mazon JJ. Addition of radiotherapy to long-term androgen deprivation in *locally advanced* prostate cancer: an open randomised phase 3 trial. *Eur Urol* 2012 Aug;62(2):213-9.
16. Murai M, Cheng Ch, Khauli R, Lee E, Sahabududdin RM, Sasidharan. Epidemiology of Prostate cancer in Asia. Dalam: McConnell J, Denis L, Akaza H, Khoury S, Schalken J.eds. Prostate cancer. 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases. 2006. h. 57-65.
17. National Comprehensive Cancer Network. Prostate Cancer (Version 1.2015). www.nccn.org/patients

18. Nakamura K, Mizowaki T, Imada H, Karasawa K, Uno T, Onishi H. External-beam radiotherapy for localized or *locally advanced* prostate cancer in Japan: a multi-institutional outcome analysis. *Jpn J Clin Oncol* 2008;38:200-4.
19. Nelson JB. Hormone Therapy for Prostate Cancer. Dalam : Campbell-Walsh Urology Tenth Edition. Philadelphia: Saunders.2012. Page 2934
20. Komite Penanggulangan Kanker Nasional. Pedoman Nasional Pelayanan Kedokteran Kanker Prostat. 2015
21. Restanto, Adhika. *Survival* Pada Pasien Kanker Prostat Yang Menjalani Terapi Hormonal. (Karya Ilmiah). Yogyakarta: Program Pendidikan Dokter Spesialis Urologi. Fakultas Kedokteran Universitas Gadjah Mada, 2015.
22. Scosyrev E, Messing EM, Mohile S. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. *Cancer*. 2012;118:3062-3070.
23. Seung Jin Moon, Sung Yul Park, Tchun Yong Lee. Predictive Factors of Gleason Score Upgrading in Localized and *Locally advanced* Prostate Cancer Diagnosed by Prostate Biopsy. *Korean J Urol* 2010;51:677-682
24. Umbas R, Mochtar CA, Hamid RA. Terapi radikal pada penderita Kanker prostat: Tindak lanjut jangka panjang dan faktor prediksi survival. *Indonesian Journal of Cancer* 2010;4(2):55-60.
25. Umbas Rainy, Hardjowijoto Sunaryo, Mochtar Chaidir A, Safriadi Ferry, Djatisoesanto Wahjoe, Soedarso MA, Danarto, Sihombing Aaron Tigor. Guideline on prostate cancer. *Indonesian Urological Association*, 2011.
26. Umbas R, Mochtar CA, Rahardjo HE. Current status of prostate cancer in Asia. *Indonesia J Cancer* 2011;5:21-4.



27. Warde P, Mason M, Ding K. and for the NCIC CTG PR.3/MRC UK PR07 investigators.

Combined androgen deprivation therapy and radiation therapy for *locally advanced* prostate cancer: a randomised, phase 3 trial. *Lancet* 2012 Dec;378(9809):2104-11.

28. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. *Lancet* 2009; 373: 301–8.

29. Wempy Supit, Chaidir Arif Mochtar, Rachmat Budi Santoso, Rainy Umbas. Outcomes and predictors of localized or locally-advanced prostate cancer treated by radiotherapy in Indonesia. *Prostate Int* 2013;1(1):16-22

30. Yun Kwan Ro *et al.*. Biochemical Recurrence in Gleason Score 7 Prostate Cancer in Korean Men: Significance of the Primary Gleason Grade. *Korean J Urol* 2012;53:826-829

31. Yuri P et al. Indonesian Prostate Cancer Risk Calculator (IPCRC) : An application for Predicting Prostate Cancer Risk (a Multicenter Study). *Acta Med Indones-Indones J Intern Med*. Vol 47 Number 2 April 2015